Combining-Topiramate-Olanzapine

Topiramate
Type moodstabilizer
Group anticonvulsant
links
ATC-code N03AX11
PubChem 5284627
PubMed Topiramate
Drugs.com topiramate
Kompas (Dutch) Topiramate
Wikipedia Topiramate
Olanzapine
Type antipsychotic
Group atypical AP
Other use moodstabilizer
links
ATC-code N05AH03
Medscape Olanzapine
EMEA zyprexa
PubChem 4585
PubMed Olanzapine
Drugs.com olanzapine
Kompas (Dutch) Olanzapine
Wikipedia Olanzapine

Adding olanzapine to topiramate.

Infobord.png General information
  • Topiramate induces CYP3A4 and is an inhibitor of CYP2C19.
  • Olanzapine is principally metabolized by CYP1A2 and CYP2D6.
  • This combination of drugs may have possible synergistic effects. However, this combination will also have additive side effects. Dose adaptation will be recommended for this combination.
Eenrichtingbord.png Start olanzapine
  • Start olanzapine according general dosing advice.
Letopbord.png Cave
  • Caution is advised when topiramate is prescribed with other drugs that predispose patients to heat-related disorders, including carbonic anhydrase inhibitors and drugs with anticholinergic activity. [5]


  1. ↑ 1.01.1 Farmacotherapeutisch Kompas - topiramaat (dutch)
  2. ↑ 2.02.12.22.3 KNMP; Informatorium Medicamentorum 2015; Monografie "olanzapine" (Dutch)
  3. ↑ Farmacotherapeutisch Kompas; Toxicologie (dutch)
  4. ↑ Woods SW Chlorpromazine equivalent doses for the newer atypical antipsychotics; J Clin Psychiatry 2003;64:663-667
  5. ↑ Interactions between olanzapine and topiramate on drugs.com
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.